Decoy Therapeutics annual free cash flow
2014
2015
2016
2017
2018
2019
2020
2021
2024
2025
Decoy Therapeutics Free Cash Flow (FCF) History (DCOY)
Decoy Therapeutics reported −$5.4M in free cash flow for fiscal 2025, a decrease of $878,851 from the previous fiscal year.
View full Decoy Therapeutics company overviewDecoy Therapeutics free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | −$5.4M | −$878,851 | — | — |
| 2024 | 2024-12-31 | −$4.5M | $5.7M | — | — |
| 2021 | 2021-12-31 | −$10.2M | $113,766 | — | −554.29% |
| 2020 | 2020-12-31 | −$10.3M | $1.3M | — | −197.08% |
| 2019 | 2019-12-31 | −$11.6M | −$15.8M | — | −334.20% |
| 2018 | 2018-12-31 | $4.2M | $32.0M | — | +214.07% |
| 2017 | 2017-12-31 | −$27.8M | $4.8M | — | −2184.05% |
| 2016 | 2016-12-31 | −$32.6M | −$11.6M | — | −3226.74% |
| 2015 | 2015-12-31 | −$21.0M | −$14.5M | — | — |
| 2014 | 2014-12-31 | −$6.6M | — | — | — |
Decoy Therapeutics quarterly free cash flow
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q4 2018 | 2018-12-31 | $387,538 | $6.2M | — | +36.62% |
| Q3 2018 | 2018-09-30 | $21.5M | $29.6M | — | +4574.68% |
| Q2 2018 | 2018-06-30 | −$8.3M | −$2.5M | — | −3362.68% |
| Q1 2018 | 2018-03-31 | −$9.4M | −$1.2M | — | −5270.68% |
| Q4 2017 | 2017-12-31 | −$5.8M | $578,464 | — | −2040.36% |
| Q3 2017 | 2017-09-30 | −$8.1M | −$624,790 | — | −1957.37% |
| Q2 2017 | 2017-06-30 | −$5.7M | $3.8M | — | −1705.26% |
| Q1 2017 | 2017-03-31 | −$8.2M | $1.0M | — | −3400.47% |
| Q4 2016 | 2016-12-31 | −$6.3M | −$869,506 | — | −2124.15% |
| Q3 2016 | 2016-09-30 | −$7.5M | −$619,751 | — | −1247.08% |
| Q2 2016 | 2016-06-30 | −$9.5M | −$5.0M | — | −8439.90% |
| Q1 2016 | 2016-03-31 | −$9.3M | −$5.1M | — | — |
| Q4 2015 | 2015-12-31 | −$5.5M | — | — | — |
| Q3 2015 | 2015-09-30 | −$6.9M | — | — | — |
| Q2 2015 | 2015-06-30 | −$4.5M | — | — | — |
| Q1 2015 | 2015-03-31 | −$4.2M | — | — | — |
Decoy Therapeutics free cash flow growth trends
Over the last five reported fiscal years, free cash flow declined from $4.2M to −$5.4M, a net decrease of $9.6M. Decoy Therapeutics's latest reported quarter, Q4 2018, generated $387,538 in free cash flow, an increase of $6.2M year over year.
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Decoy Therapeutics filings at SEC.gov ↗